Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Overall Study	STARTED	Aliskiren	821
Overall Study	STARTED	Placebo	818
Overall Study	Safety Set	Aliskiren	808
Overall Study	Safety Set	Placebo	810
Overall Study	Full Analysis Set	Aliskiren	808
Overall Study	Full Analysis Set	Placebo	807
Overall Study	Completed Primary Efficacy Phase (6 m)	Aliskiren	717
Overall Study	Completed Primary Efficacy Phase (6 m)	Placebo	707
Overall Study	Completed Secondary Efficacy Phase (12m)	Aliskiren	654
Overall Study	Completed Secondary Efficacy Phase (12m)	Placebo	640
Overall Study	COMPLETED	Aliskiren	646
Overall Study	COMPLETED	Placebo	643
Overall Study	NOT COMPLETED	Aliskiren	175
Overall Study	NOT COMPLETED	Placebo	175

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00894387/flow